Sector News

Categories

Borderless Insights

Image
Negotiating Terms with a New Employer
Image
Beyond Flowers and Platitudes: Reclaiming the Essence of International Women’s Day
Image
Visionary or ‘Stuck-in-the-Mud’? Where are you on Workplace Flexibility?

Stryker eyes deals, market share growth in Europe

January 15, 2015
Life sciences
(Reuters) – Orthopedic device and surgical equipment maker Stryker Corp said on Wednesday it is eyeing growth through acquisitions, and has set its sights on improving market share for its products in Europe.
 
Stryker Chief Executive Kevin Lobo, speaking at the JP Morgan healthcare conference in San Francisco, said the company was in a very strong cash position that would allow it to make acquisitions that are “small, medium or even large.”
 
“We need to be market leaders in the areas that we choose to play in,” Lobo said. “We’ll look at deals of all different sizes … to strengthen our position.”
 
Stryker plans to repatriate some $2 billion in cash held overseas in the second half of 2015.
 
The company on Tuesday cautioned that the strength of the U.S. dollar versus overseas currencies would take a larger than previously expected toll on 2015 earnings, shaving some 20 cents from per share profit versus its prior view of 10 to 12 cents.
 
Stryker currently has about two thirds of its total sales in the United States, with about a quarter coming from other developed markets and 8 percent from emerging markets.
 
Lobo sees Europe as a critical area with room for improving Stryker’s performance, and said he believes the capital spending climate there is improving.
 
“Our market shares are dramatically lower in Europe than in the U.S., Canada or Japan,” he said. “Our products should be garnering higher market share there.”
 
Stryker has altered its corporate structure so that operations in Europe will now report directly to the United States.
 
Despite the challenging environment in some emerging markets, such as Russia, Lobo said Stryker aims to increase its percentage of total sales from developing markets “to get to double digits in the next few years.”
 
Stryker shares were down $2.20, or 2.3 percent, at $92.02 on the New York Stock Exchange.
 
(Reporting by Bill Berkrot in New York; Editing by Bernard Orr)

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

Read more
April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

Read more
April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

Read more
More news

How can we help you?

We're easy to reach